Mark Pedersen
Overview
Explore the profile of Mark Pedersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pedersen M, Timperley J, Mason B, Al-Refaie W
Am J Surg
. 2025 Jan;
116189.
PMID: 39837729
No abstract available.
2.
Montano-Loza A, Lytvyak E, Hirschfield G, Hansen B, Ebadi M, Berney T, et al.
J Hepatol
. 2024 May;
81(4):679-689.
PMID: 38821360
Background & Aims: Recurrent primary biliary cholangitis (rPBC) develops in approximately 30% of patients and negatively impacts graft and overall patient survival after liver transplantation (LT). There is a lack...
3.
Anouti A, Al Hariri M, VanWagner L, Lee W, Mufti A, Pedersen M, et al.
Dig Dis Sci
. 2024 Feb;
69(4):1488-1495.
PMID: 38381224
Background: Living-donor liver transplantation (LDLT) has been increasing in the USA. While data exist on longer-term patient and graft outcomes, a contemporary analysis of short-term outcomes is needed. Aim: Evaluate...
4.
Anouti A, Patel M, VanWagner L, Lee W, Asrani S, Mufti A, et al.
Liver Transpl
. 2023 Jul;
30(1):72-82.
PMID: 37490432
Recent deceased-donor allocation changes in the United States may have increased high-Model for End-Stage Liver Disease (MELD) living donor liver transplantation (LDLT); however, outcomes in these patients remain poorly defined....
5.
Schroeder M, Pedersen M, Petrasek J, Grant L
Hepatol Commun
. 2023 May;
7(5).
PMID: 37141503
Background: Liver transplant (LT) is a highly effective therapy for refractory severe alcohol-associated hepatitis (SAH), but optimal selection criteria remain unknown. We aim to evaluate the outcomes of patients who...
6.
Montano-Loza A, Ronca V, Ebadi M, Hansen B, Hirschfield G, Elwir S, et al.
J Hepatol
. 2022 Feb;
77(1):84-97.
PMID: 35143897
Background & Aims: Autoimmune hepatitis can recur after liver transplantation (LT), though the impact of recurrence on patient and graft survival has not been well characterized. We evaluated a large,...
7.
Pedersen M
Gastroenterol Hepatol (N Y)
. 2021 Oct;
17(9):439-442.
PMID: 34602910
No abstract available.
8.
Muna-Aguon P, Ramanathan M, Choi M, Pedersen M, Seetharam A
Clin Exp Hepatol
. 2020 Jan;
5(4):279-284.
PMID: 31893238
Aim Of The Study: Utilization of direct acting antiviral (DAA) therapy in candidates with well-compensated hepatitis C virus (HCV) cirrhosis and hepatocellular carcinoma (HCC) accruing end stage liver disease (MELD)...
9.
DeAndrade J, Pedersen M, Garcia L, Nau P
J Surg Res
. 2017 Dec;
221:161-166.
PMID: 29229123
Background: Sarcopenia is an independent risk factor for adverse outcomes in critically ill patients. The impact of sarcopenia on morbidity and length of stay in a trauma population has not...
10.
Pedersen M, Cromwell J, Nau P
Inflamm Bowel Dis
. 2017 Jun;
23(10):1867-1872.
PMID: 28604415
Background: Sarcopenia is associated with an increased risk of operative morbidity and mortality. The impact of sarcopenia in inflammatory bowel disease (IBD) has not been evaluated. This study assessed the...